Clover Health Investments, Corp. — Q2 2023 Form 10-Q Summary
Business context and reporting period
Clover Health operates Medicare Advantage PPO and HMO plans through its Insurance segment and participates in CMS's ACO REACH Model through its Non-Insurance segment. Its Clover Assistant technology supports physicians in identifying and managing chronic conditions. This unaudited Form 10-Q covers the three and six months ended June 30, 2023, compared with the corresponding 2022 periods.
- At June 30, 2023, Insurance membership was 82,526 and aligned Non-Insurance beneficiaries were 52,393, for 134,919 total lives under management.
- Insurance plans operated in eight states and 220 counties at quarter-end. Beginning in 2024, management expects coverage in five states and 200 counties.
- The Company strategically reduced ACO REACH participating physicians and aligned beneficiaries during the 2023 performance year.
Key financial metrics
| Metric | Three months ended June 30, 2023 | Three months ended June 30, 2022 | Six months ended June 30, 2023 | Six months ended June 30, 2022 |
|---|---|---|---|---|
| Total revenue | $513.6 million | $846.7 million | $1,041.4 million | $1,721.1 million |
| Premiums earned, net | $314.4 million | $268.5 million | $631.5 million | $546.7 million |
| Non-Insurance revenue | $193.5 million | $577.4 million | $399.3 million | $1,172.3 million |
| Net medical claims incurred | $437.0 million | $858.8 million | $909.4 million | $1,720.5 million |
| Loss from operations | $(28.8) million | $(102.7) million | $(101.4) million | $(190.2) million |
| Net loss | $(28.8) million | $(104.4) million | $(101.4) million | $(179.9) million |
| Net loss per share | $(0.06) | $(0.22) | $(0.21) | $(0.38) |
| Net cash provided by operating activities | Not separately reported for the quarter | $132.2 million | $(96.2) million |
- Insurance medical care ratio was 81.9% for the six months ended June 30, 2023, compared with 94.3% in the prior-year period.
- Non-Insurance medical care ratio was 97.8%, compared with 102.9% in the prior-year period.
- Cash, cash equivalents and restricted cash totaled $392.8 million at June 30, 2023, including $310.1 million of cash and cash equivalents and $82.7 million of restricted cash.
- Total assets were $1.258 billion, total liabilities were $927.4 million, and stockholders’ equity was $330.6 million at June 30, 2023.
- The filing reports no material debt financing arrangements and only $7 thousand of interest expense for the six-month period.
- Total investment securities at fair value were $272.4 million. All fixed-maturity securities were investment grade, with ratings of BBB+ or higher.
Material changes versus the prior comparable period
- Total revenue declined 39.3% in the second quarter and 39.5% for the six-month period, primarily because Non-Insurance revenue declined 66.5% and 65.9%, respectively, following the strategic reduction in aligned ACO REACH beneficiaries.
- Premiums earned increased 17.1% in the quarter and 15.5% year to date, driven principally by higher CMS premiums associated with the Company's 3.0-to-3.5 Star Rating and improved risk-adjustment revenue.
- Net loss improved by $75.5 million in the quarter and $78.4 million year to date. The improvement primarily reflects lower Non-Insurance medical claims, lower personnel and general and administrative costs, and improved Insurance medical care ratios.
- Net cash from operating activities improved to $132.2 million from $96.2 million of cash used in the prior-year period. The 2023 amount benefited from a $113.5 million CMS prepayment for July 2023 and noncash stock-based compensation of $74.7 million.
- The Company recorded $6.6 million of restructuring costs year to date, including employee termination benefits, vendor costs and other costs, compared with none in the prior-year period.
- Stock-based compensation declined to $74.7 million from $82.6 million year to date, but remained a significant operating expense. Unrecognized stock-based compensation was approximately $469.5 million at June 30, 2023, excluding the separate $59.3 million related to performance awards.
- The Company adopted a change in its premium deficiency reserve methodology to include anticipated future investment income. The change reduced the June 30, 2023 reserve by $2.4 million and increased reported six-month 2023 net income by $6.8 million versus the former method.
Guidance, outlook, commentary and risks
- Management states that available cash, investments and projected operating cash flows are expected to satisfy projected operating and regulatory requirements for at least the next 12 months under current plans. The Company also cautions that additional equity or debt financing may be required, potentially on unfavorable or dilutive terms.
- Business transformation initiatives include migrating core Medicare Advantage plan operations to UST HealthProof's technology platform and a workforce reduction of approximately 10%. Total restructuring costs are expected to be approximately $7.0 million to $9.0 million, with the remainder substantially incurred over the next 12 months.
- The Company assumes full risk for ACO REACH shared savings and shared losses. At June 30, 2023, it recorded a $441.4 million Non-Insurance performance-year obligation and a $377.2 million performance-year receivable. The maximum potential future payment under the performance guarantee cannot be estimated clearly because of stop-loss arrangements, corridors, risk ratings and benchmark trends.
- On July 12, 2023, an agreement with CMS and a third party enabled the Company to release $30.0 million of restricted cash, reducing escrowed restricted cash to $52.7 million.
- A securities class-action settlement is subject to final court approval. The proposed settlement is $22.0 million; the Company received $19.5 million of insurance proceeds, deposited $7.7 million into escrow by June 30, 2023, and expected to deposit the remaining $14.3 million in the third quarter. The Company continues litigation against certain insurers seeking additional recovery.
- Derivative litigation settlements are subject to definitive documentation and court approval and contemplate corporate governance enhancements, with no monetary payment other than undetermined plaintiffs’ counsel fees and expenses.
- The Company received formal Nasdaq notice on July 31, 2023 that it had regained compliance with the $1.00 minimum bid-price requirement. Stockholders were scheduled to vote on August 30, 2023 on authorization for a potential 1-for-5 to 1-for-20 reverse stock split.
- Key ongoing risks include medical-cost and claims-reserve estimation, ACO REACH benchmark and risk-score development, regulatory and Medicare policy changes, Star Ratings, liquidity and capital needs, litigation and investigations, provider-network performance, and Nasdaq listing compliance.
Most important facts for investors to verify
- Whether the improvement in loss and Insurance medical care ratio is sustained after the benefit of reserve changes and restructuring actions.
- The financial impact of the substantially smaller ACO REACH beneficiary base and the ultimate shared-savings or shared-loss reconciliation.
- The adequacy and liquidity of restricted cash, regulatory capital and investments held at regulated insurance subsidiaries, which cannot freely be distributed to the parent.
- The final court approval, funding and insurance recoveries related to the $22.0 million securities litigation settlement.
- The timing, cost and operational effects of the UST HealthProof transition and workforce reduction.
- The potential dilution from outstanding equity awards and the approximately $469.5 million of unrecognized stock-based compensation expense.
- The outcome of the proposed reverse stock split and continued Nasdaq listing status.
- The development of unpaid claims, risk-adjustment estimates, premium deficiency reserves and ACO REACH performance obligations, all of which rely materially on management estimates.